可扩展性
计算机科学
鉴定(生物学)
推论
计算生物学
药物发现
表型
概化理论
机器学习
转录组
深度学习
基因组学
人工智能
临床表型
主动学习(机器学习)
模拟生物系统
缩放比例
系统生物学
表型筛选
签名(拓扑)
药物重新定位
疾病
精密医学
药物反应
药物靶点
生物信息学
不相关
生物网络
计算模型
药物开发
生物
作者
Benjamin DeMeo,Charlotte Nesbitt,Samuel A. Miller,Daniel B. Burkhardt,Inna Lipchina,Doris Fu,Peter Holderreith,David Kim,Sergey Kolchenko,Artur Szałata,Ishan Gupta,Christine Kerr,T. Joshua Pfefer,Raziel Rojas-Rodriguez,Sunil Kuppassani,Laurens Kruidenier,Parul B. Doshi,Mahdi Zamanighomi,James J. Collins,Alex K. Shalek
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2025-10-23
卷期号:390 (6776): eadi8577-eadi8577
被引量:31
标识
DOI:10.1126/science.adi8577
摘要
Phenotypic drug screening remains constrained by the vastness of chemical space and the technical challenges of scaling experimental workflows. To overcome these barriers, computational methods have been developed to prioritize compounds, but they rely on either single-task models lacking generalizability or heuristic-based genomic proxies that resist optimization. We designed an active deep learning framework that leverages omics to enable scalable, optimizable identification of compounds that induce complex phenotypes. Our generalizable algorithm outperformed state-of-the-art models on classical recall, translating to a 13- to 17-fold increase in phenotypic hit rate across two hematological discovery campaigns. Combining this algorithm with a lab-in-the-loop signature refinement step, we achieved an additional twofold increase in hit rate along with molecular insights. In sum, our framework enables efficient phenotypic hit identification campaigns, with broad potential to accelerate drug discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI